参附注射液治疗高原地区慢性肺源性心脏病合并心力衰竭的疗效观察

Effects of treating chronic pulmonary heart disease complicated with heart failure in plateau area with Shenfu injection.

目的观察参附注射液治疗气虚血淤型慢性肺源性心脏病合并心力衰竭的临床疗效。方法采用随机对照法将96例患者分为治疗组56例和对照组40例，2组均给予基础治疗，治疗组在基础治疗的基础上加用参附注射液60～80ml加入5％葡萄糖注射液或0．9％的氯化钠注射液150ml中静脉滴注，15d为一疗程，共2个疗程。观察2组治疗前后中医症候以及左心室射血分数（LVEF）、B型尿钠肽（BNP）的变化。结果治疗组临床总有效率达91．1％（51／56），明显高于对照组[72．5％（29／40），Х^2=8．545，P〈0．05]；治疗后治疗组LVEF明显高于对照组[（53．27±7．45）％与（49．12±5．89）％，t=2．165，P〈0．05]，BNP较对照组明显降低[（209．1±18．7）、（261．2±19．3）ng／L，t=2．284，P〈0．05]。结论参附注射液能增强心肌收缩力，增加LVEF，从而显著改善左心室功能；降低BNP，纠正心力衰竭。

Objective To assess the clinical effects of Shenfu injection which consists mainly of panaxoside and water-solubility alkaloied on chronic pulmonary heart disease complicated with heart failure. Methods Ninetysix patients were randomly divided into two groups,40 patients underwent regular treatment （control group） and 56 patients were treated with Shenfu injection additionally to regular treatment （treatment group）. There were 2 treatment durations,with 15 days in one duration. The symptoms,left ventricular ejection fraction （LVEF）and B type UNa peptide （BNP） were measured before and after treatment. Results The total effective rate in the treatment group was 91.1% （51/56） ,which was significantly higher than that in the control group （72. 5% ,29/40） （P 〈 0. 05）. After treatment, the treatment group has significantly higher LVEF than the control group（53.27% ± 7.45% vs. 49. 12% ±5.89% ） （P 〈0. 05） ,and significantly lower BNP （ （209. 1 ± 18. 7） ng/L vs. （261.2 ± 19.3） ng/L （ P 〈 0. 05 ）. Conclusions Shenfu injection could strengthen the contractility and increase LVEF, therefore improve the function of left ventricle, as well as decrease BNP and repair heart failure.